| Literature DB >> 30781400 |
Imelda Seminerio1, Géraldine Descamps2, Sophie Dupont3, Lisa de Marrez4, Jean-Alexandre Laigle5, Jérôme R Lechien6, Nadège Kindt7, Fabrice Journe8, Sven Saussez9.
Abstract
Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a large heterogeneity in terms of the location and risk factors. For a few years now, immunotherapy seems to be a promising approach in the treatment of these cancers, but a better understanding of the immune context could allow to offer a personalized treatment and thus probably increase the survival of HNSCC patients. In this context, we evaluated the infiltration of FoxP3+ Tregs on 205 human formalin-fixed paraffin-embedded HNSCC and we assessed its prognostic value compared to other potential prognostic factors, including HPV infection. First, we found a positive correlation of FoxP3+ Treg infiltration between the intra-tumoral (IT) and the stromal (ST) compartments of the tumors (p < 0.0001). A high infiltration of these cells in both compartments was associated with longer recurrence-free (ST, RFS, p = 0.007; IT, RFS, p = 0.019) and overall survivals (ST, OS, p = 0.002; ST, OS, p = 0.002) of HNSCC patients. Early tumor stage (OS, p = 0.002) and differentiated tumors (RFS, p = 0.022; OS, p = 0.043) were also associated with favorable prognoses. Multivariate analysis revealed that FoxP3+ Treg stromal infiltration, tumor stage and histological grade independently influenced patient prognosis. In conclusion, the combination of these three markers seem to be an interesting prognostic signature for HNSCC.Entities:
Keywords: FoxP3+ Tregs; HNSCC; HPV; histological grade; prognosis; tumor stage
Year: 2019 PMID: 30781400 PMCID: PMC6406934 DOI: 10.3390/cancers11020227
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Treg immunostaining on HNSCC tumors. (A) FoxP3/CD4 double immunofluorescence on HNSCC tumors. Nuclear red and membrane green fluorescent markers correspond to FoxP3 and CD4 stainings, respectively; blue staining is from DAPI. (B) FoxP3 immunohistochemistry in stromal (ST) and intra-tumoral (IT) compartments of HNSCC tumor.
Characteristics of patient population used in this study. p values < 0.05 are highlighted in bold.
| Variables | Number of Cases ( | ||
|---|---|---|---|
| Age (years) | |||
| Median | 61 | ||
| Range | 29–90 | ||
| Gender |
| 0.21 | |
| Male | 138 | ||
| Female | 67 | ||
| Anatomic site |
|
| |
| Oral cavity | 99 | ||
| Oropharynx | 59 | ||
| Larynx | 32 | ||
| Hypopharynx | 14 | ||
| Nasopharynx | 1 | ||
| Tumor stage | 0.497 | 0.748 | |
| T1isN0 | 1 | ||
| T1N0 | 42 | ||
| T2N0 | 31 | ||
| T1N1 | 5 | ||
| T2N1 | 8 | ||
| T3N0 | 9 | ||
| T3N1 | 4 | ||
| T1N2 | 4 | ||
| T2N2 | 16 | ||
| T3N2 | 13 | ||
| T3N3 | 1 | ||
| T4aN0 | 24 | ||
| T4aN1 | 10 | ||
| T4aN2 | 19 | ||
| T4aN3 | 1 | ||
| T4bN2 | 1 | ||
| Unknown | 16 | ||
| Histological grade (differentiation) | 0.1 | 0.806 | |
| Undifferentiated | 26 | ||
| Moderate | 69 | ||
| Well | 96 | ||
| Unknown | 14 | ||
| Tumor invasion | 0.238 | 0.649 | |
| Yes | 142 | ||
| None | 54 | ||
| Unknown | 9 | ||
| Risk factors | |||
| Tobacco | 0.768 | 0.81 | |
| Smoker | 160 | ||
| Non smoker | 35 | ||
| Unknown | 10 | ||
| Alcohol | 0.732 | 0.72 | |
| Drinker | 111 | ||
| Non drinker | 73 | ||
| Unknown | 21 | ||
| HPV status | 0.814 | 0.502 | |
| Negative | 127 | ||
| Positive | 35 | ||
| p16 status | 0.064 |
| |
| Negative | 112 | ||
| Positive | 14 | ||
| HPV/p16 status | 0.357 | 0.097 | |
| Negative | 127 | ||
| Positive, p16 negative | 24 | ||
| Positive, p16 positive | 11 | ||
| Unknown | 43 | ||
| Recurrence (RFS) | |||
| Median (months) | 23 | ||
| Range (months) | 1–245 | ||
| Yes | 98 | ||
| None | 107 | ||
| Overall survival (OS) | |||
| Median (months) | 33 | ||
| Range (months) | 1–294 | ||
| Alive | 106 | ||
| Dead | 88 |
* N < 205 because some tumor samples were non-evaluable for FoxP3 expression (less than 5 fields in ST and/or IT areas for counting).
Figure 2Association between FoxP3+ Treg infiltration and patient survival in HNSCC. (A) Association between FoxP3+ Tregs infiltration in the stromal compartment and recurrence-free survival (RFS) of patients. (B) Association between FoxP3+ Tregs infiltration in the stromal compartment and overall survival (OS) of patients. (C) Association between FoxP3+ Tregs infiltration in the intra-tumoral compartment and RFS of patients. (D) Association between FoxP3+ Tregs infiltration in the intra-tumoral compartment and OS of patients.
Figure 3Association between tumor clinical characteristics and prognosis in HNSCC. (A) Association between tumor stage and recurrence-free survival (RFS) of patients. (B) Association between tumor stage and overall survival (OS) of patients. (C) Association between tumor histological grade and RFS of patients. (D) Association between tumor histological grade and OS of patients.
Correlation between patient clinical data and recurrence-free (RFS) and overall survivals (OS). p values < 0.05 are highlighted in bold.
|
| RFS | OS | ||
|---|---|---|---|---|
|
|
| |||
|
| ||||
| Tregs ST (>63.15 vs. <63.15) | 2.08 (1.22–3.57) |
| 2.23 (1.35–3.69) |
|
| Tregs IT (>17.2 vs. <17.2) | 1.96 (1.11–3.44) |
| 2.19 (1.21–3.98) |
|
| Gender (male vs. female) | 1.43 (0.95–2.15) | 0.084 | 1.05 (0.69–1.60) | 0.812 |
| Tumor stage (I–II vs. III–IV) | 1.42 (0.90–2.23) | 0.122 | 2.20 (1.34–3.61) |
|
| Histological grade (differentiated vs. undifferentiated) | 2.01 (1.10–3.67) |
| 1.82 (1.01–3.25) |
|
| Tumor invasion (invasion vs. no invasion) | 1.60 (0.93–2.74) | 0.086 | 1.41 (0.85–2.33) | 0.183 |
| Tobacco (smokers vs. no smokers) | 1.35 (0.77–2.36) | 0.284 | 1.30 (0.74–2.27) | 0.356 |
| Alcohol (drinkers vs. no drinkers) | 1.11 (0.72–1.72) | 0.618 | 1.15 (0.74–1.80) | 0.519 |
| HPV status (positive vs. negative) | 1.54 (0.87–2.71) | 0.131 | 1.16 (0.69–1.95) | 0.562 |
| p16 status (positive vs. negative) | 2.12 (0.76–5.91) | 0.148 | 1.86 (0.67–5.18) | 0.229 |
|
| ||||
| Tregs ST (>63.15 vs. <63.15) | 2.24 (1.00–5.02) |
| 2.32 (1.17–4.58) |
|
| Tregs IT (>17.2 vs. <17.2) | 1.85 (0.94–3.64) | 0.074 | 1.79 (0.92–3.47) | 0.083 |
| Tumor stage (I–II vs. III–IV) | 3.33 (1.44–7.70) |
| 3.72 (1.59–8.73) |
|
| Histological grade (differentiated vs. undifferentiated) | 4.76 (2.00–11.36) |
| 2.53 (1.08–5.88) |
|
Figure 4Association between combined Treg infiltration in the stromal compartment, tumor stage and tumor histological grade and prognosis in HNSCC. (A) Association between the three combined prognostic markers and recurrence-free survival of HNSCC patients. (B) Association between the three combined prognostic markers and overall survival of HNSCC patients. High score means that all the markers or two of the three markers are of good prognosis. Low score means that one of the three markers or none of the three markers are of good prognosis.